Yüklüyor......
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiothe...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6607970/ https://ncbi.nlm.nih.gov/pubmed/31297338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00560 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|